Glenn Heller

Q: What Schools Are Affiliated With Glenn Heller

Glenn Heller is affiliated with the following schools: Columbia University, Massachusetts General Hospital, University of Florida College of Medicine, New York University, University of Western Australia, University of California, Berkeley, Université de Montréal, Yale University, Medical College of Wisconsin, Rockefeller University, Stanford University

Glenn Heller's AcademicInfluence.com Rankings

Glenn Heller

Engineering

#5252

World Rank

#6500

Historical Rank

Electrical Engineering

#1447

World Rank

#1541

Historical Rank

engineering Degrees

Glenn Heller

Computer Science

#6740

World Rank

#7104

Historical Rank

Computational Linguistics

#1228

World Rank

#1242

Historical Rank

Machine Learning

#2288

World Rank

#2316

Historical Rank

Artificial Intelligence

#2561

World Rank

#2602

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Glenn Heller's Degrees

PhD Computer Science Stanford University
Masters Electrical Engineering University of California, Berkeley
Bachelors Computer Engineering University of California, Berkeley

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Glenn Heller Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Glenn Heller's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. (2011) (1159)
Cardiac toxicity 4 to 20 years after completing anthracycline therapy. (1991) (958)
Genomic correlates of clinical outcome in advanced prostate cancer (2019) (647)
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. (1992) (641)
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer (2007) (632)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. (2009) (579)
Concordance probability and discriminatory power in proportional hazards regression (2005) (577)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. (2016) (540)
Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin (2000) (507)
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. (2009) (499)
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. (2005) (490)
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. (2002) (463)
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. (2005) (384)
Osteogenic sarcoma with clinically detectable metastasis at initial presentation. (1993) (370)
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. (2012) (366)
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation : Effect of patient age and donor leukocyte infusions (1999) (351)
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer (2007) (335)
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. (2015) (330)
Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. (1996) (328)
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia (1991) (314)
Expression of HER2/erbB-2 correlates with survival in osteosarcoma. (1999) (312)
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. (2008) (300)
Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. (1998) (295)
Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. (1994) (292)
All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study (1994) (288)
Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. (2002) (288)
T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection (2007) (278)
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer (2007) (274)
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. (2000) (272)
IL-17 contributes to CD4-mediated graft-versus-host disease. (2009) (266)
Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. (2006) (251)
Clinical states in prostate cancer: toward a dynamic model of disease progression. (2000) (241)
Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. (1998) (231)
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. (2011) (229)
Altered bone and mineral metabolism in patients receiving imatinib mesylate. (2006) (229)
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes (2003) (217)
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. (1998) (212)
The Histological Response to Chemotherapy as a Predictor of the Oncological Outcome of Operative Treatment of Ewing Sarcoma* (1998) (211)
Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group. (1998) (210)
Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer (2009) (208)
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. (2011) (208)
The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. (1996) (203)
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. (2011) (203)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. (2012) (203)
Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts (1989) (202)
Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. (1991) (202)
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. (2004) (201)
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. (1999) (201)
Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation (2006) (200)
Recurrence and morbidity in differentiated thyroid carcinoma in children. (1988) (187)
Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. (1994) (183)
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. (2001) (183)
The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis (1996) (182)
Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. (2002) (182)
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. (2000) (177)
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer (2018) (174)
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. (1994) (170)
Pediatric desmoid tumor: retrospective analysis of 63 cases. (1995) (164)
B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. (1990) (163)
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. (2001) (160)
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. (1999) (158)
The impact of gross total resection on local control and survival in high-risk neuroblastoma. (2004) (153)
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. (1995) (153)
Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells1 (2004) (152)
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. (2012) (151)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. (2017) (151)
Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands1 (2007) (147)
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. (2017) (145)
Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. (2010) (143)
Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. (1994) (140)
Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. (1997) (140)
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. (2003) (139)
Neuroblastoma metastatic to the central nervous system (2001) (137)
Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards (2005) (136)
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. (2011) (128)
LPAM (α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease (2004) (124)
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (123)
Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy (2005) (123)
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors (2008) (121)
Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. (1992) (117)
N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. (2001) (114)
Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. (2006) (113)
The effect of age at diagnosis on outcome in rhabdomyosarcoma (1994) (112)
Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. (2019) (109)
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. (1991) (109)
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. (1992) (106)
Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. (1995) (106)
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants (1989) (106)
Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. (2001) (106)
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study (2007) (105)
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. (2017) (103)
A competing‐risks nomogram for sarcoma‐specific death following local recurrence (2003) (102)
Bone Mineral Density in Young Adult Survivors of Childhood Cancer (1998) (101)
Growth in children after bone marrow transplantation for acute leukemia. (1995) (101)
Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands (2007) (101)
CCR2 is required for CD8-induced graft-versus-host disease. (2005) (101)
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acet (2011) (99)
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant. (2020) (99)
Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. (1990) (98)
Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. (2011) (97)
Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells. (2005) (97)
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake (2016) (93)
Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy (2005) (92)
A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. (1991) (92)
Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The memorial Sloan‐Kettering‐New York‐II protocol (1993) (91)
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. (2009) (89)
Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. (1989) (89)
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. (1989) (89)
Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. (1994) (88)
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. (1989) (85)
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. (2011) (83)
T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. (1992) (83)
Validation and clinical utility of prostate cancer biomarkers (2013) (82)
Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? (1997) (80)
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. (2011) (80)
Fludarabine‐based cytoreductive regimen and T‐cell‐depleted grafts from alternative donors for the treatment of high‐risk patients with Fanconi anaemia (2008) (80)
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. (2004) (79)
Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. (2000) (78)
Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. (1998) (77)
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. (1998) (77)
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. (2011) (76)
Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetat (2011) (76)
Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. (1994) (75)
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. (2014) (75)
All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study (1997) (75)
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. (2020) (74)
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. (2008) (73)
Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. (2010) (72)
The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer (2007) (70)
A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions. (2009) (70)
High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma. (1998) (70)
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer (2020) (70)
Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. (1999) (70)
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. (2014) (69)
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease (2007) (68)
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. (2003) (67)
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. (2020) (67)
Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo (2011) (66)
Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. (2004) (65)
Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. (2002) (65)
Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. (1992) (65)
Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis (1997) (63)
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. (2010) (62)
Direct evidence for new T-cell generation by patients after either T-cell–depleted or unmodified allogeneic hematopoietic stem cell transplantationsPresented in part in abstract form at the 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, December 2000. (2002) (61)
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials (2006) (61)
KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. (2016) (61)
Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile (2018) (60)
Pediatric rhabdomyosarcoma of the head and neck. (1997) (58)
Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. (2000) (57)
Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation (2007) (56)
Human Epidermal Growth Factor Receptor 2 as a Prognostic Indicator in Osteogenic Sarcoma (2001) (54)
Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease. (2010) (53)
Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. (1993) (52)
Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. (2005) (52)
Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). (2011) (50)
An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment. (2010) (49)
Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. (2016) (49)
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high‐dose chemotherapy plus granulocyte‐macrophage colony‐stimulating factor a randomized trial (1993) (49)
Second Malignant Neoplasms in Long‐Term Survivors of Childhood Rhabdomyosarcoma (1995) (48)
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. (2012) (48)
In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity (2004) (48)
The phase II/III transition. Toward the proof of efficacy in cancer clinical trials. (2000) (47)
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population (2016) (47)
Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant (2017) (47)
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients (2016) (46)
Prediction in censored survival data: a comparison of the proportional hazards and linear regression models. (1992) (46)
Smoothed Rank Regression With Censored Data (2007) (45)
DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. (1999) (44)
Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants (2013) (44)
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. (2013) (44)
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. (2007) (44)
Septicemia and Septic Shock in Pediatric Patients: 140 Consecutive Cases on a Pediatric Hematology‐Oncology Service (1998) (43)
A measure of explained risk in the proportional hazards model. (2012) (43)
A comparison of estimators for regression with a censored response variable (1990) (42)
A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. (1994) (42)
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. (2017) (42)
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. (2007) (40)
Quantifying the amount of variation in survival explained by prostate-specific antigen. (2002) (39)
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). (2019) (37)
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer (2021) (37)
Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. (1996) (37)
Prevalence of vitamin D insufficiency in survivors of childhood cancer (2013) (36)
Estimating the concordance probability in a survival analysis with a discrete number of risk groups (2016) (35)
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors (2012) (32)
Second-line chemotherapy for prostate cancer: patient characteristics and survival. (2005) (32)
Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses. (2016) (31)
The probability of HLA-C matching between patient and unrelated donor at the molecular level: estimations based on the linkage disequilibrium between DNA typed HLA-B and HLA-C alleles. (1999) (31)
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. (2008) (30)
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. (2007) (30)
Organ-derived dendritic cells have differential effects on alloreactive T cells. (2008) (30)
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions (2021) (29)
Mortality in pediatric paratesticular rhabdomyosarcoma: a multivariate analysis. (1989) (29)
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. (2020) (29)
Proportional hazards regression with interval censored data using an inverse probability weight (2011) (28)
Lehmann Family of ROC Curves (2010) (27)
Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications (2015) (27)
Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT (2010) (27)
Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. (1994) (27)
Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. (2009) (26)
Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer (2006) (26)
Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. (2010) (26)
Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade (2016) (25)
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. (2013) (25)
Picking the winners in a sea of plenty. (2002) (24)
Factors associated with relapse and survival in Wilms tumor: a multivariate analysis. (2012) (24)
Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics (2019) (22)
Growth and Final Height After Treatment for Childhood Hodgkin Disease (1996) (22)
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. (2004) (20)
Repetitively dosed docetaxel and 153samarium‐EDTMP as an antitumor strategy for metastatic castration‐resistant prostate cancer (2013) (20)
Granulocyte‐colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator‐based combination chemotherapy in children with neuroblastoma (2000) (20)
Soluble and membrane‐bound interleukin (IL)‐15 Rα/IL‐15 complexes mediate proliferation of high‐avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections (2016) (20)
Langerhans Cells Derived from Genetically Modified Human CD34+ Hemopoietic Progenitors Are More Potent Than Peptide-Pulsed Langerhans Cells for Inducing Antigen-Specific CD8+ Cytolytic T Lymphocyte Responses1 (2005) (18)
DNA Immunization against Tissue-Restricted Antigens Enhances Tumor Immunity after Allogeneic Hemopoietic Stem Cell Transplantation1 (2006) (18)
Assessing outcomes in prostate cancer clinical trials (2008) (18)
IFN-γ and Fas Ligand Are Required for Graft-versus-Tumor Activity against Renal Cell Carcinoma in the Absence of Lethal Graft-versus-Host Disease1 (2007) (17)
Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. (2006) (17)
The use of back-up units to enhance the safety of unrelated donor cord blood transplantation. (2012) (16)
HLA-C disparity between patients and unrelated donors matched for HLA-A, -B, and -DRB1 alleles: impact of serological vs. DNA typing for HLA-A and -B loci. (1999) (14)
Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8 (1999) (14)
Inference for the difference in the area under the ROC curve derived from nested binary regression models. (2016) (14)
Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate? (1999) (13)
CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia. (1993) (13)
Seventh Edition of TNM Classification for Gastric Cancer (2011) (13)
Prognosis in childhood rhabdomyosarcoma of the extremity (1989) (12)
High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal irradiation on hematopoietic recovery. (1996) (12)
CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. (2020) (11)
IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease. (2007) (11)
Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. (1994) (10)
CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC). (2019) (10)
Efficacy analysis of a phase III study of androgen deprivation therapy (ADT) +/- docetaxel (D) for men with biochemical relapse (BCR) after prostatectomy. (2015) (10)
Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering. (1993) (9)
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial. (2003) (9)
Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine. (1997) (9)
Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity. (1991) (9)
Successful treatment of diamond‐blackfan anemia with interleukin 3 (1993) (9)
Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria. (2015) (8)
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen. (2005) (8)
Langerhans-Type Dendritic Cells Genetically Modified to Express Full-Length Antigen Optimally Stimulate CTLs in a CD4-Dependent Manner1 (2006) (8)
Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for SelfHLA SelfHLA SelfHLA-B and HLAC HLAC HLAC Ligands 1 (2007) (7)
Primary peripheral nodal lymphoma in children (1993) (7)
Interleukin-1 production following T-cell-depleted and unmodified marrow grafts. (1996) (7)
Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib (2021) (7)
Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC). (2018) (6)
Hypothyroidism after 131I‐monoclonal antibody treatment of neuroblastoma (2010) (6)
KIR and HLA genotypes have no identifiable role in single unit dominance following double unit umbilical cord blood transplantation (2014) (6)
Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib (2015) (6)
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). (2021) (6)
Dose-intensity analysis and randomized trials. (1991) (5)
Evidence that appearance of thymulin in plasma follows lymphoid chimerism and precedes development of immunity in patients with lethal combined immunodeficiency transplanted with T cell-depleted haploidentical marrow. (1990) (5)
CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC). (2021) (5)
Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. (2010) (5)
Scalable Expansion of Potent Genetically Modified Human Langerhans Cells in a Closed System for Clinical Applications (2007) (5)
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. (2022) (5)
Retrospective review of neoadjuvant chemotherapy for osteogenic sarcoma. (1992) (5)
Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy (2002) (5)
Improving the Decision to Pursue a Phase 3 Clinical Trial by Adjusting for Patient-Specific Factors in Evaluating Phase 2 Treatment Efficacy Data (2007) (5)
LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER (2019) (4)
Adoptive transfer of in vitro generated T cell precursors improves T cell reconstitution and mediates graft-versus-tumor activity without graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients (2006) (4)
Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy (2022) (4)
Adoptive Transfer of In Vitro Generated T Cell Precursors Enhances Donor T Cell Reconstitution and Graft-Versus-Tumor Activity in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. (2005) (4)
Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8 (1993) (4)
Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro. (1990) (4)
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers (2021) (4)
A “No-Wash” Albumin-Dextran Dilution Strategy for Cord Blood (CB) Thaw is Associated with a High Rate of Engraftment and a Low Incidence of Serious Infusion Reactions (2009) (3)
Inference on the Limiting False Discovery Rate and the P-value Threshold Parameter Assuming Weak Dependence between Gene Expression Levels within Subject (2007) (3)
Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data (2010) (3)
Risk assessment for severe hypocalcemia requiring hospitalization with denosumab. (2013) (3)
In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma. (1995) (3)
Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials. (2017) (3)
Power calculations for preclinical studies using a K‐sample rank test and the Lehmann alternative hypothesis (2006) (3)
Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa). (2019) (3)
Zr-J 591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (3)
Outcomes with second-line chemotherapy in castrate metastatic prostate cancer (2005) (3)
A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19). (2018) (3)
“No Wash” Albumin-Dextran Dilution for Double-Unit Cord Blood Transplantation (DCBT) Is Safe with Appropriate Management and Results in High Rates of Sustained Donor Engraftment (2012) (3)
The added value of new covariates to the brier score in cox survival models (2020) (2)
Two Chemotherapy-Based Conditioning Regimens Compared To TBI-Based Conditioning Secure Consistent Engraftment Of T-Cell Depleted Allogeneic HSCT, Similarly Low Incidences Of Gvhd and Favorable Rates Of Disease-Free Survival (DFS) (2013) (2)
Correlating surrogate endpoints with overall survival at the individual patient level in BRAF-mutated metastatic melanoma patients treated with vemurafenib. (2015) (2)
Translating prostate cancer working group (PCWG) criteria into a quantitative progression biomarker in metastatic castration resistant prostate cancer (mCRPC). (2017) (2)
Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data. (2010) (2)
T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation with Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients with Relapsed Multiple Myeloma and High-Risk Cytogenetics (2011) (2)
Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. (2022) (2)
Absence of the (cid:1) 7 Integrin Results in Less Graft-Versus-Host Disease Due to Decreased Homing of Alloreactive T Cells to Intestine (2005) (2)
Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer. (2020) (2)
Incorporating Follow-up Time in M-Estimation for Survival Data (2004) (2)
A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. (2021) (2)
Inhibition of NF-κB DNA binding suppresses myeloma growth via intracellular redox and tumor microenvironment modulation. (2022) (2)
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of 17-Allylamino-17-demethoxygeldanamycin (17AAG) in children with solid tumors. (2006) (2)
Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer. (2013) (2)
Selection of Unrelated Allogeneic Hematopoietic Cell Donors Based on KIR3DL1 Allotypes Is Feasible and Results in Improved Disease-Free Survival in Transplant Recipients with MDS and AML (2016) (2)
Recombinant Human Interleukin-7 (CYT107) Promotes T Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantion (2011) (2)
Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301. (2017) (2)
18F-16β-fluoro-5α-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC). (2012) (1)
Response: Sample size and statistical comparisons of GVHD rates in pediatric Niemann-Pick disease patients. (2010) (1)
KIR-HLA Genotypes Have No Identifiable Role in Unit Predominance Following Double Unit Cord Blood Transplantation (2011) (1)
Radiation Therapy Prostate-Specific Antigen Values following Surgery or Time to Detectable Metastatic Disease in Patients with Rising Updated (2005) (1)
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. (2022) (1)
Fluorodeoxyglucose Positron EmissionTomography as an Outcome Measure for CastrateMetastatic Prostate CancerTreatedwith Antimicrotubule Chemotherapy (2005) (1)
CC chemokine receptor 2 is required for CD 8-induced graft-versus-host disease (2005) (1)
Early Immune Recovery Predicts Overall and Disease-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation. (2009) (1)
Inferential Methods to Assess the Difference in the Area Under the Curve From Nested Binary Regression Models (2015) (1)
Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC): the MEN's Cycle (2004) (1)
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy (2021) (1)
Clinical validation of CTC subtype frequency to prognosis OS in mCRPC patients. (2016) (1)
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC). (2022) (1)
The Activating KIR2DS2 Gene Influences NK Alloreactivity and NK Repertoire. (2007) (1)
Pre-Engraftment Syndrome (PES): A Clinical Syndrome After Cord Blood (CB) Transplantation Not Associated with Acute Graft-Versus-Host Disease (aGvHD) or Transplant-Related Mortality (TRM) (2009) (1)
Concordance probability as a meaningful contrast across disparate survival times (2020) (1)
Human Langerhans cells electroporated with Wilms’ tumor 1 mRNA induce antigen-specific cytolytic T lymphocytes (2008) (1)
Recombinant Human Interleukin-7 (CYT107) Enhances CD4 and CD8 T Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant In Patients with Myeloid Malignancies (2010) (1)
A Phase I/II Study for Analytic Validation of Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer (2015) (1)
Circulating tumor cells in patients with castration-resistant metastatic prostate cancer (2007) (1)
Advances in Brief The Histone Deacetylase Inhibitor , CBHA , Inhibits Growth of Human Neuroblastoma Xenografts in Vivo , Alone and Synergistically with All-Trans Retinoic Acid 1 (2001) (1)
Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer (2022) (1)
Evaluating 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) and FDG PET as prognostic biomarkers for patients (pts) treated with abiraterone acetate (AA). (2014) (1)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Speci ﬁ c Antigen Across Five Randomized Phase III Clinical Trials (2018) (1)
Induction of Remission Prior to Transplantation Improves the Disease-Free Survival (DFS) of Patients with Advanced Myelodysplastic Syndromes (MDS) Treated with Myeloablative T-Cell Depleted (TCD) Stem Cell Transplants (SCT) from HLA Identical Siblings. (2005) (0)
Calculating the Concordance Probability Estimate with a Discrete Number of Risk Groups (2013) (0)
Abstract 3282: Does the catalytic activity of prostate-specific antigen (PSA) or kallikrein-related peptidase 2 (hK2) secreted by novel transgenic mice models critically influence development of prostate cancer or release of PSA or hK2 in blood (2012) (0)
Abstract 2459: KIR3DL1 and HLA-B subtype combinations predict the efficacy of 3F8 monoclonal antibody therapy for neuroblastoma (2015) (0)
Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP). (2018) (0)
TransplantationAllogeneic Hemopoietic Stem Cell Antigens Enhances Tumor Immunity after DNA Immunization against Tissue-Restricted (2006) (0)
Viral Infections Are the Greatest Cause Of Infectious Mortality After Cord Blood (CB) Transplantation (CBT) But the Mortality Risk Is Limited to the First 4 Months (2009) (0)
Leukocytosis a nd t he R etinoic A cid S yndrome i n P atients With A cute P romyelocytic L eukemia T reated W ith A rsenic Trioxide (2000) (0)
Paclitaxel, E stramustine P hosphate, a nd C arboplatin i n Patients W ith A dvanced P rostate C ancer (2006) (0)
#686 The evaluation of IGF‐1 as a possible promoter for EBV lymphoma in vitro and in vivo (1998) (0)
Leveraging CD39 To Identify Tumor-Reactive CD8 T cells In Human Lung Cancer (2022) (0)
Targeted Janus Kinase-2 Inhibition Overcomes Limitations of Il6-Receptor-Alpha Blockade in Controlling Human DC-Stimulated Alloreactivity (2012) (0)
Microenvironment and Immunology In vivo Inhibition of HumanCD 19-Targeted Effector TCells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy (2011) (0)
Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC): the MEN's Cycle. (2004) (0)
Measuring the temporal prognostic utility of a baseline risk score (2020) (0)
Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC). (2013) (0)
Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic prostate cancer. (2010) (0)
Serum granulocyte colony-stimulating factor (G-CSF) levels after allogeneic T cell-depleted marrow transplantation. (1995) (0)
Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer. (2019) (0)
B-cell ontogeny depleted bone marrow transplantation: a recapitulation of normal B-cell differentiation following autologous, conventional, or T-cell (2011) (0)
Fluorescence In situ Hybridization Analysis of CirculatingTumor Cells in Metastatic Prostate Cancer (2009) (0)
Reply to M. Fink (2011) (0)
Does CTCAE toxicity symptom reporting by patients or clinicians predict clinical outcomes (2008) (0)
The Analytical Validation of Prostate Specific Mrna Detection in Whole Blood by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) as a Prognostic Biomarker for Patients with Castration-Resistant Prostate Cancer (CRPC) (2012) (0)
Expression o f H ER2/ erbB-2 C orrelates W ith S urvival in O steosarcoma (1999) (0)
A model assessing how variable timing of outcome assessments impacts progression-free survival (PFS) (2007) (0)
Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. (2022) (0)
The analytic validation of prostate-specific mRNA detection in whole blood by RT-PCR as a prognostic biomarker for patients with castration-resistant prostate cancer (CRPC). (2012) (0)
Pairwise rank based likelihood for estimating the relationship between two homogeneous populations and their mixture proportion (2005) (0)
265: A Constitutively Activated Mutant form of Propsa that Manifests Catalytic Action Increases Cell Invasion in Vitro and Frequency of Pulmonary Metastases in vivo in a Subcutaneous Mouse Xenograft Model (2007) (0)
Optimally Stimulate CTLs in a Modified to Express Full-Length Antigen Langerhans-Type Dendritic Cells Genetically (2013) (0)
Advances in Brief Response of Prostate Cancer to Anti-Her-2 / neu Antibody in Androgen-dependent and-independent Human Xenograft Models 1 (1999) (0)
Successful Treatment of Acute Gastrointestinal (GI) Graft-Versus-Host Disease (GVHD) After Cord Blood Transplantation (CBT) With Single Agent Budesonide (2011) (0)
CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer (2022) (0)
Self-HLA-B and HLA-C Ligands Quantity of Inhibitory Receptors for Response Is Determined by Class and Hierarchy of the Human Natural Killer Cell (2007) (0)
LPAM ( (cid:1) 4 (cid:2) 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease (2004) (0)
A Novel Reduced Intensity Conditioning Can Induce a High Incidence of Sustained Donor Engraftment After Double Unit Cord Blood Transplantation (CBT) without Anti-Thymocyte Globulin (2010) (0)
Allogeneic B one M arrow T ransplantation V ersus Chemotherapy f or t he T reatment o f C hildhood A cute Lymphoblastic L eukemia i n S econd R emission: A S ingle-Instituti on S tudy (1999) (0)
A retropective analysis of colorectal cancer in adolescents and young adults: A report from the Surgical Committee of the Children's Oncology Group (2007) (0)
Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC) (2016) (0)
CirculatingTumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer (2007) (0)
Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone? Reply (2016) (0)
Effect of Peri-transplant Linezolid on Time to Neutrophil and Platelet Engraftment after Allogeneic Stem Cell Transplantation (HSCT) (2008) (0)
A six-gene panel that predicts survival in men with castration-resistant prostate cancer. (2011) (0)
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). (2023) (0)
Host T-Cells Contribute to Immune Reconstitution and Improved Outcome in Recipients of CD34 Selected T-Cell Depleted Allografts (TCD HCT) with Full Hematopoietic Cell but Persistent Mixed T-Cell Chimerism (2020) (0)
CirculatingTumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer (2007) (0)
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen? Reply (2018) (0)
Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). (2021) (0)
Bone marrow transplantation for myelodysplastic syndromes and secondary acute myelocytic leukemia (1994) (0)
Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK 1 / 2 Blockade Running Title : DCs mitigate NK dysfunction from JAK 1 / 2 inhibition (2016) (0)
KGF Promotes CD4+ T Cell Recovery After T-Cell Depleted Allogeneic Hematopoeitic Stem Cell Transplantation in Patients Conditioned With Total Body Irradiation: Impact on Overall Survival (2011) (0)
#633 HLA‐DQBI disparity between patients and unrelated marrow donors (URD) matched for HLA‐A, B, and -DRBI by DNA typing (1998) (0)
Validation of Flow Cytometric Measurements of NK Cytotoxicity Against Chromium Release Assay for Use in Clinical Monitoring of Immune Function. (2006) (0)
#632 HLA‐C disparity between patients and unrelated donors (URD) matched for HLA‐A, -B, and -DRVI alleles by DNA typing (1998) (0)
TheAssociation BetweenMeasures of Progression and Survival in Castrate-Metastatic Prostate Cancer (2007) (0)
Title : Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer (2017) (0)
Defining a new threshold for PSA outcomes in untreated prostate cancer (2004) (0)
A07 The Genomic Landscape of SMARCA4 Alterations and Association with Patient Outcomes in Lung Cancer (2020) (0)
Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19). (2023) (0)
PCK3145, a novel multitargeted signalling agent for the treatment of castrate metastatic prostate cancer (CMPC) (2007) (0)
Absolute Lymphocyte Count At Day 30 Predicts Survival In Recipients Of A T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (2009) (0)
Defining a new threshold for PSA outcomes in untreated prostate cancer. (2004) (0)
Long-Term Survival After T-Cell Depleted Allogeneic Stem Cell Transplantation in Patients With Acute Lymphoblastic Leukemia (2011) (0)
Advances in Brief 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2 / neu and Inhibits the Growth of Prostate Cancer Xenografts 1 (2002) (0)
Characterization of the tumor-specific activity of WT1 specific T cells generated in vitro from normal individuals by sensitization with WT1-peptide loaded autologous EBV transformed B cells (2004) (0)
Analysis of Failure and Survival Data (2003) (0)
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. (2022) (0)
Human Langerhans-Type Dendritic Cells Break Tolerance against the Tumor Antigen, WT1, by a Largely IL-15-Dependent Mechanism. (2008) (0)
555. Langerhans cells modified by gene transfer of full length CMV pp65 are more potent inducers of cytolytic T lymphocytes in a CD4-dependent manner than either CMV p495 gene-modified or p495 peptide-pulsed langerhans cells (2004) (0)
' s report Title : External validation of a Cox prognostic model : principles and methods Version : 2 (2013) (0)
LBA02-11 UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19) (2023) (0)
Association of age, baseline characteristics, co-morbidity and toxicity in castrate metastatic prostate cancer patients (CMPC) treated with chemotherapy (2005) (0)
EVALUATION OF A MULTIMODAL STRATEGY TO ACCELERATE DRUG EVALUATIONS IN EARLY STAGE METASTATIC PROSTATE CANCER: PD24‐11 (2017) (0)
Prevention of mucositis with KGF in patients undergoing allogeneic stem cell transplantation. (2011) (0)
Outcomes of Two Chemotherapy-Based Preparatory Regimens Compared to TBI-Based Conditioning When Used with CD34+ Selected T-Cell Depleted Allohct for High Risk Hematologic Malignancies: Prospective Clinical Trial NCT 01119066 (2020) (0)
Reply to A. Addeo and A. Bahl. (2016) (0)
Retrospective Analysis of Standard Versus Mini-Dose Methotrexate in the Prevention of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplant Recipients (2012) (0)
Evaluation of a multimodal strategy to accelerate drug evaluations in early-stage metastatic prostate cancer. (2017) (0)
Abstract 4954: Nuclear localized AR-V7 protein as a predictive biomarker for treatment selection in metastatic castration resistant prostate cancer (mCRPC) (2016) (0)
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC). (2023) (0)
Analysis of circulating prostate tumor cells by fluorescence in situ hybridization (2008) (0)
Reply to C. Ren et al. (2018) (0)
graft-versus-host disease and induces Th2 deviation Absence of inducible costimulator on alloreactive T cells reduces (2013) (0)
Circulating tumor cells as prognostic biomarkers in patients with metastatic prostate cancer (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Glenn Heller?

Glenn Heller is affiliated with the following schools:

Glenn Heller's Academic­Influence.com Rankings

Glenn Heller's Degrees

Similar Degrees You Can Earn

Why Is Glenn Heller Influential?

Glenn Heller's Published Works

Published Works

What Schools Are Affiliated With Glenn Heller?

Glenn Heller's AcademicInfluence.com Rankings